Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.

Georg Pilz; Andrea Harrer; Katrin Oppermann; Peter Wipfler; Stefan Golaszewski; S Afazel; Elisabeth Haschke-Becher; Eugen Trinka; Jörg Kraus

doi:10.1177/1352458511423650

Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.

Georg Pilz^* (First author), Andrea Harrer (Co-author), Katrin Oppermann (Co-author), Peter Wipfler (Co-author), Stefan Golaszewski (Co-author), S Afazel, Elisabeth Haschke-Becher (Co-author), Eugen Trinka (Co-author), Jörg Kraus (Last author)

^*Corresponding author for this work

Department of Neurology

Research output: Contribution to journal › Original Article › peer-review

10 Citations (Web of Science)

Original language	English
Pages (from-to)	506-509
Journal	MULTIPLE SCLEROSIS
Volume	18
Issue number	4
DOIs	https://doi.org/10.1177/1352458511423650
Publication status	Published - 2012

Keywords

RELAPSING MULTIPLE-SCLEROSIS
CONTROLLED TRIAL
MARKERS

Access to Document

10.1177/1352458511423650

Cite this

Pilz, G., Harrer, A., Oppermann, K., Wipfler, P., Golaszewski, S., Afazel, S., Haschke-Becher, E., Trinka, E., & Kraus, J. (2012). Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies. MULTIPLE SCLEROSIS , 18(4), 506-509. https://doi.org/10.1177/1352458511423650

Pilz, Georg ; Harrer, Andrea ; Oppermann, Katrin et al. / Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies. In: MULTIPLE SCLEROSIS 2012 ; Vol. 18, No. 4. pp. 506-509.

@article{9cd0df392bf74fd4b4bb78b8ee9ebd3c,

title = "Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.",

keywords = "RELAPSING MULTIPLE-SCLEROSIS, CONTROLLED TRIAL, MARKERS",

author = "Georg Pilz and Andrea Harrer and Katrin Oppermann and Peter Wipfler and Stefan Golaszewski and S Afazel and Elisabeth Haschke-Becher and Eugen Trinka and J{\"o}rg Kraus",

note = "alle: Paracelsus Medical University, Salzburger Landeskliniken; Christian-Doppler-Klinik, Department of Neurology, Salzburg, Austria",

year = "2012",

doi = "10.1177/1352458511423650",

language = "English",

volume = "18",

pages = "506--509",

journal = "MULTIPLE SCLEROSIS ",

issn = "1352-4585",

number = "4",

}

Pilz, G , Harrer, A, Oppermann, K, Wipfler, P, Golaszewski, S, Afazel, S, Haschke-Becher, E, Trinka, E & Kraus, J 2012, 'Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.', MULTIPLE SCLEROSIS , vol. 18, no. 4, pp. 506-509. https://doi.org/10.1177/1352458511423650

Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies. / Pilz, Georg (First author); Harrer, Andrea (Co-author); Oppermann, Katrin (Co-author) et al.
In: MULTIPLE SCLEROSIS , Vol. 18, No. 4, 2012, p. 506-509.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.

AU - Pilz, Georg

AU - Harrer, Andrea

AU - Oppermann, Katrin

AU - Wipfler, Peter

AU - Golaszewski, Stefan

AU - Afazel, S

AU - Haschke-Becher, Elisabeth

AU - Trinka, Eugen

AU - Kraus, Jörg

N1 - alle: Paracelsus Medical University, Salzburger Landeskliniken; Christian-Doppler-Klinik, Department of Neurology, Salzburg, Austria

PY - 2012

Y1 - 2012

KW - RELAPSING MULTIPLE-SCLEROSIS

KW - CONTROLLED TRIAL

KW - MARKERS

U2 - 10.1177/1352458511423650

DO - 10.1177/1352458511423650

M3 - Original Article

C2 - 21965415

SN - 1352-4585

VL - 18

SP - 506

EP - 509

JO - MULTIPLE SCLEROSIS

JF - MULTIPLE SCLEROSIS

IS - 4

ER -

Pilz G , Harrer A, Oppermann K, Wipfler P, Golaszewski S, Afazel S et al. Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies. MULTIPLE SCLEROSIS . 2012;18(4):506-509. doi: 10.1177/1352458511423650